What is MiMedx Group Inc (MDXG) stock price today?

MiMedx Group Inc (MDXG) currently trades at $3.36 per share. The stock has a market capitalization of $458.33M and a P/E ratio of 9.64x.

Is MDXG stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, MiMedx Group Inc has a Smart Value Score of 74/100 (Grade B), resulting in a "Buy" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is the MDXG stock price target for 2026?

WallStSmart's 12-month price target for MiMedx Group Inc is $5.12.

What is MiMedx Group Inc's revenue and earnings?

MiMedx Group Inc has trailing twelve-month (TTM) revenue of $418.63M with profit margins of 11.60%. Earnings per share (EPS) is $0.32.

MDXG

MiMedx Group Inc

NASDAQ: MDXG · HEALTHCARE · BIOTECHNOLOGY

$3.36

+8.91% today

Updated 2026-04-30

Market cap

$458.33M

P/E ratio

9.64

P/S ratio

1.10x

EPS (TTM)

$0.32

Dividend yield

—

52W range

$3 – $8

Volume

1.4M

Market cap

$458.33M

P/E ratio

9.64

P/S ratio

1.10x

EPS (TTM)

$0.32

Dividend yield

—

52W range

$3 – $8

Volume

1.4M

WallStSmart proprietary scores

out of 100

Grade: B

Buy

Investment rating

8.7

Growth

5.0

Quality

C+

7.5

Profitability

B+

5.7

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$8.00

+138.10%

12-Month target

$5.12

+52.38%

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ ROE 21.60% — strong efficiency

+ Free cash flow $24.58M — positive

+ Revenue growth 27.10% QoQ

Risks

No major risks identified

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$267.84M	$321.48M	$348.88M	$418.63M	$418.63M
Net income	$-30.20M	$67.44M	$42.42M	$48.58M	$15.19M
EPS	—	—	—	—	$0.32
Free cash flow	$-20.58M	$24.79M	$64.52M	$72.97M	$24.58M
Profit margin	-11.27%	20.98%	12.16%	11.60%	11.60%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-13	MAERSK-MOLLER, KIMBERLY	Sale	6,762	$4.38
2026-03-13	HULSE, WILLIAM FRANK IV	Sale	20,245	$4.38
2026-03-10	MAERSK-MOLLER, KIMBERLY	Buy	42,845	$4.50

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MDXG	$458.33M	74	8.7	7.5	5.7	5.0	—	Strong Buy
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

MiMedx Group Inc trades at $3.36. representing a P/E of 9.64x trailing earnings. Our Smart Value Score of 74/100 indicates the stock is good. TTM revenue stands at $418.63M. with profit margins at 11.60%.

Frequently asked questions

What is MiMedx Group Inc's stock price?

MiMedx Group Inc (MDXG) trades at $3.36.

Is MiMedx Group Inc overvalued?

Smart Value Score 74/100 (Grade B, Buy).

What is the price target of MiMedx Group Inc (MDXG)?

The analyst target price is $8.00, representing +138.1% upside from the current price of $3.36.

What is the future stock price of MDXG by 2030?

Our revenue-driven model estimates MiMedx Group Inc could reach $6.36 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.

What is MiMedx Group Inc's revenue?

TTM revenue is $418.63M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.10x

ROE21.60%

Beta1.65

50D MA$4.19

200D MA$6.07

Shares out0.15B

Float0.12B

Short ratio—

Avg volume1.4M

Performance

1 week+7.19%

1 month-9.97%

3 months-35.28%

YTD-49.34%

1 year—

3 years—

5 years—

Compare

MDXG vs LLY →MDXG vs JNJ →MDXG vs ABBV →Stock screener →